Skip to content

Glycerol phenylbutyrate

Ravicti (glycerol phenylbutyrate) is a small molecule pharmaceutical. Glycerol phenylbutyrate was first approved as Ravicti on 2013-02-01. It has been approved in Europe to treat inborn urea cycle disorders. Ravicti's patent is valid until 2032-03-09 (FDA).
Trade Name Ravicti
Common Name Glycerol phenylbutyrate
Indication inborn urea cycle disorders
Drug Class
Glycerol phenylbutyrate
Get full access now